SCFFBW7 regulates cellular apoptosis by targeting MCL1 for ubiquitylation and destruction

Hiroyuki Inuzuka, Shavali Shaik, Ichiro Onoyama, Daming Gao, Alan Tseng, Richard S. Maser, Bo Zhai, Lixin Wan, Alejandro Gutierrez, Alan W. Lau, Yonghong Xiao, Amanda L. Christie, Jon Aster, Jeffrey Settleman, Steven P. Gygi, Andrew L. Kung, Thomas Look, Keiichi Nakayama, Ronald A. Depinho, Wenyi Wei

Research output: Contribution to journalArticle

356 Citations (Scopus)

Abstract

The effective use of targeted therapy is highly dependent on the identification of responder patient populations. Loss of FBW7, which encodes a tumour-suppressor protein, is frequently found in various types of human cancer, including breast cancer, colon cancer and T-cell acute lymphoblastic leukaemia (T-ALL). In line with these genomic data, engineered deletion of Fbw7 in mouse T cells results in T-ALL, validating FBW7 as a T-ALL tumour suppressor. Determining the precise molecular mechanisms by which FBW7 exerts antitumour activity is an area of intensive investigation. These mechanisms are thought to relate in part to FBW7-mediated destruction of key proteins relevant to cancer, including Jun, Myc, cyclin E and notch 1 (ref. 9), all of which have oncoprotein activity and are overexpressed in various human cancers, including leukaemia. In addition to accelerating cell growth, overexpression of Jun, Myc or notch 1 can also induce programmed cell death. Thus, considerable uncertainty surrounds how FBW7-deficient cells evade cell death in the setting of upregulated Jun, Myc and/or notch 1. Here we show that the E3 ubiquitin ligase SCFFBW7 (a SKP1-cullin-1-F-box complex that contains FBW7 as the F-box protein) governs cellular apoptosis by targeting MCL1, a pro-survival BCL2 family member, for ubiquitylation and destruction in a manner that depends on phosphorylation by glycogen synthase kinase 3. Human T-ALL cell lines showed a close relationship between FBW7 loss and MCL1 overexpression. Correspondingly, T-ALL cell lines with defective FBW7 are particularly sensitive to the multi-kinase inhibitor sorafenib but resistant to the BCL2 antagonist ABT-737. On the genetic level, FBW7 reconstitution or MCL1 depletion restores sensitivity to ABT-737, establishing MCL1 as a therapeutically relevant bypass survival mechanism that enables FBW7-deficient cells to evade apoptosis. Therefore, our work provides insight into the molecular mechanism of direct tumour suppression by FBW7 and has implications for the targeted treatment of patients with FBW7-deficient T-ALL.

Original languageEnglish
Pages (from-to)104-109
Number of pages6
JournalNature
Volume471
Issue number7336
DOIs
Publication statusPublished - Mar 3 2011

Fingerprint

Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
Ubiquitination
Apoptosis
Colonic Neoplasms
Neoplasms
Cell Death
F-Box Proteins
Breast Neoplasms
Tumor Suppressor Proteins
Glycogen Synthase Kinase 3
Cell Line
Cyclin E
Ubiquitin-Protein Ligases
Survival
Oncogene Proteins
Uncertainty
Leukemia
Phosphotransferases
Phosphorylation
T-Lymphocytes

All Science Journal Classification (ASJC) codes

  • General

Cite this

Inuzuka, H., Shaik, S., Onoyama, I., Gao, D., Tseng, A., Maser, R. S., ... Wei, W. (2011). SCFFBW7 regulates cellular apoptosis by targeting MCL1 for ubiquitylation and destruction. Nature, 471(7336), 104-109. https://doi.org/10.1038/nature09732

SCFFBW7 regulates cellular apoptosis by targeting MCL1 for ubiquitylation and destruction. / Inuzuka, Hiroyuki; Shaik, Shavali; Onoyama, Ichiro; Gao, Daming; Tseng, Alan; Maser, Richard S.; Zhai, Bo; Wan, Lixin; Gutierrez, Alejandro; Lau, Alan W.; Xiao, Yonghong; Christie, Amanda L.; Aster, Jon; Settleman, Jeffrey; Gygi, Steven P.; Kung, Andrew L.; Look, Thomas; Nakayama, Keiichi; Depinho, Ronald A.; Wei, Wenyi.

In: Nature, Vol. 471, No. 7336, 03.03.2011, p. 104-109.

Research output: Contribution to journalArticle

Inuzuka, H, Shaik, S, Onoyama, I, Gao, D, Tseng, A, Maser, RS, Zhai, B, Wan, L, Gutierrez, A, Lau, AW, Xiao, Y, Christie, AL, Aster, J, Settleman, J, Gygi, SP, Kung, AL, Look, T, Nakayama, K, Depinho, RA & Wei, W 2011, 'SCFFBW7 regulates cellular apoptosis by targeting MCL1 for ubiquitylation and destruction', Nature, vol. 471, no. 7336, pp. 104-109. https://doi.org/10.1038/nature09732
Inuzuka, Hiroyuki ; Shaik, Shavali ; Onoyama, Ichiro ; Gao, Daming ; Tseng, Alan ; Maser, Richard S. ; Zhai, Bo ; Wan, Lixin ; Gutierrez, Alejandro ; Lau, Alan W. ; Xiao, Yonghong ; Christie, Amanda L. ; Aster, Jon ; Settleman, Jeffrey ; Gygi, Steven P. ; Kung, Andrew L. ; Look, Thomas ; Nakayama, Keiichi ; Depinho, Ronald A. ; Wei, Wenyi. / SCFFBW7 regulates cellular apoptosis by targeting MCL1 for ubiquitylation and destruction. In: Nature. 2011 ; Vol. 471, No. 7336. pp. 104-109.
@article{e7fb3fee3aaa4a359f1091d68d458312,
title = "SCFFBW7 regulates cellular apoptosis by targeting MCL1 for ubiquitylation and destruction",
abstract = "The effective use of targeted therapy is highly dependent on the identification of responder patient populations. Loss of FBW7, which encodes a tumour-suppressor protein, is frequently found in various types of human cancer, including breast cancer, colon cancer and T-cell acute lymphoblastic leukaemia (T-ALL). In line with these genomic data, engineered deletion of Fbw7 in mouse T cells results in T-ALL, validating FBW7 as a T-ALL tumour suppressor. Determining the precise molecular mechanisms by which FBW7 exerts antitumour activity is an area of intensive investigation. These mechanisms are thought to relate in part to FBW7-mediated destruction of key proteins relevant to cancer, including Jun, Myc, cyclin E and notch 1 (ref. 9), all of which have oncoprotein activity and are overexpressed in various human cancers, including leukaemia. In addition to accelerating cell growth, overexpression of Jun, Myc or notch 1 can also induce programmed cell death. Thus, considerable uncertainty surrounds how FBW7-deficient cells evade cell death in the setting of upregulated Jun, Myc and/or notch 1. Here we show that the E3 ubiquitin ligase SCFFBW7 (a SKP1-cullin-1-F-box complex that contains FBW7 as the F-box protein) governs cellular apoptosis by targeting MCL1, a pro-survival BCL2 family member, for ubiquitylation and destruction in a manner that depends on phosphorylation by glycogen synthase kinase 3. Human T-ALL cell lines showed a close relationship between FBW7 loss and MCL1 overexpression. Correspondingly, T-ALL cell lines with defective FBW7 are particularly sensitive to the multi-kinase inhibitor sorafenib but resistant to the BCL2 antagonist ABT-737. On the genetic level, FBW7 reconstitution or MCL1 depletion restores sensitivity to ABT-737, establishing MCL1 as a therapeutically relevant bypass survival mechanism that enables FBW7-deficient cells to evade apoptosis. Therefore, our work provides insight into the molecular mechanism of direct tumour suppression by FBW7 and has implications for the targeted treatment of patients with FBW7-deficient T-ALL.",
author = "Hiroyuki Inuzuka and Shavali Shaik and Ichiro Onoyama and Daming Gao and Alan Tseng and Maser, {Richard S.} and Bo Zhai and Lixin Wan and Alejandro Gutierrez and Lau, {Alan W.} and Yonghong Xiao and Christie, {Amanda L.} and Jon Aster and Jeffrey Settleman and Gygi, {Steven P.} and Kung, {Andrew L.} and Thomas Look and Keiichi Nakayama and Depinho, {Ronald A.} and Wenyi Wei",
year = "2011",
month = "3",
day = "3",
doi = "10.1038/nature09732",
language = "English",
volume = "471",
pages = "104--109",
journal = "Nature",
issn = "0028-0836",
publisher = "Nature Publishing Group",
number = "7336",

}

TY - JOUR

T1 - SCFFBW7 regulates cellular apoptosis by targeting MCL1 for ubiquitylation and destruction

AU - Inuzuka, Hiroyuki

AU - Shaik, Shavali

AU - Onoyama, Ichiro

AU - Gao, Daming

AU - Tseng, Alan

AU - Maser, Richard S.

AU - Zhai, Bo

AU - Wan, Lixin

AU - Gutierrez, Alejandro

AU - Lau, Alan W.

AU - Xiao, Yonghong

AU - Christie, Amanda L.

AU - Aster, Jon

AU - Settleman, Jeffrey

AU - Gygi, Steven P.

AU - Kung, Andrew L.

AU - Look, Thomas

AU - Nakayama, Keiichi

AU - Depinho, Ronald A.

AU - Wei, Wenyi

PY - 2011/3/3

Y1 - 2011/3/3

N2 - The effective use of targeted therapy is highly dependent on the identification of responder patient populations. Loss of FBW7, which encodes a tumour-suppressor protein, is frequently found in various types of human cancer, including breast cancer, colon cancer and T-cell acute lymphoblastic leukaemia (T-ALL). In line with these genomic data, engineered deletion of Fbw7 in mouse T cells results in T-ALL, validating FBW7 as a T-ALL tumour suppressor. Determining the precise molecular mechanisms by which FBW7 exerts antitumour activity is an area of intensive investigation. These mechanisms are thought to relate in part to FBW7-mediated destruction of key proteins relevant to cancer, including Jun, Myc, cyclin E and notch 1 (ref. 9), all of which have oncoprotein activity and are overexpressed in various human cancers, including leukaemia. In addition to accelerating cell growth, overexpression of Jun, Myc or notch 1 can also induce programmed cell death. Thus, considerable uncertainty surrounds how FBW7-deficient cells evade cell death in the setting of upregulated Jun, Myc and/or notch 1. Here we show that the E3 ubiquitin ligase SCFFBW7 (a SKP1-cullin-1-F-box complex that contains FBW7 as the F-box protein) governs cellular apoptosis by targeting MCL1, a pro-survival BCL2 family member, for ubiquitylation and destruction in a manner that depends on phosphorylation by glycogen synthase kinase 3. Human T-ALL cell lines showed a close relationship between FBW7 loss and MCL1 overexpression. Correspondingly, T-ALL cell lines with defective FBW7 are particularly sensitive to the multi-kinase inhibitor sorafenib but resistant to the BCL2 antagonist ABT-737. On the genetic level, FBW7 reconstitution or MCL1 depletion restores sensitivity to ABT-737, establishing MCL1 as a therapeutically relevant bypass survival mechanism that enables FBW7-deficient cells to evade apoptosis. Therefore, our work provides insight into the molecular mechanism of direct tumour suppression by FBW7 and has implications for the targeted treatment of patients with FBW7-deficient T-ALL.

AB - The effective use of targeted therapy is highly dependent on the identification of responder patient populations. Loss of FBW7, which encodes a tumour-suppressor protein, is frequently found in various types of human cancer, including breast cancer, colon cancer and T-cell acute lymphoblastic leukaemia (T-ALL). In line with these genomic data, engineered deletion of Fbw7 in mouse T cells results in T-ALL, validating FBW7 as a T-ALL tumour suppressor. Determining the precise molecular mechanisms by which FBW7 exerts antitumour activity is an area of intensive investigation. These mechanisms are thought to relate in part to FBW7-mediated destruction of key proteins relevant to cancer, including Jun, Myc, cyclin E and notch 1 (ref. 9), all of which have oncoprotein activity and are overexpressed in various human cancers, including leukaemia. In addition to accelerating cell growth, overexpression of Jun, Myc or notch 1 can also induce programmed cell death. Thus, considerable uncertainty surrounds how FBW7-deficient cells evade cell death in the setting of upregulated Jun, Myc and/or notch 1. Here we show that the E3 ubiquitin ligase SCFFBW7 (a SKP1-cullin-1-F-box complex that contains FBW7 as the F-box protein) governs cellular apoptosis by targeting MCL1, a pro-survival BCL2 family member, for ubiquitylation and destruction in a manner that depends on phosphorylation by glycogen synthase kinase 3. Human T-ALL cell lines showed a close relationship between FBW7 loss and MCL1 overexpression. Correspondingly, T-ALL cell lines with defective FBW7 are particularly sensitive to the multi-kinase inhibitor sorafenib but resistant to the BCL2 antagonist ABT-737. On the genetic level, FBW7 reconstitution or MCL1 depletion restores sensitivity to ABT-737, establishing MCL1 as a therapeutically relevant bypass survival mechanism that enables FBW7-deficient cells to evade apoptosis. Therefore, our work provides insight into the molecular mechanism of direct tumour suppression by FBW7 and has implications for the targeted treatment of patients with FBW7-deficient T-ALL.

UR - http://www.scopus.com/inward/record.url?scp=79952261405&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79952261405&partnerID=8YFLogxK

U2 - 10.1038/nature09732

DO - 10.1038/nature09732

M3 - Article

VL - 471

SP - 104

EP - 109

JO - Nature

JF - Nature

SN - 0028-0836

IS - 7336

ER -